Phibro Animal Health's full-year guidance assumes minimal sales of virginiamycin in Brazil, the company says. The company says its 2027 net sales guidance of $1.55 billion to $1.60 billion reflects a prudent approach to regulatory uncertainty, as Phibro hasn't yet obtained required therapeutic indications for the product in Brazil. The company says a favorable regulatory outcome before the current phase-out period expires could provide modest upside. The guidance represents 4% growth, with continued expansion expected across its Animal Health, Mineral Nutrition and Performance Products segments.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.